Personal profile

Dr. Wen Zhuoqian, Associate professor of Sun Yat-sen School of Medicine, Sun Yat-sen University, doctoral supervisor, Sun Yat-sen University talent introduction, "Yixian Scholars Program" new scholars.
In 2013, he received his PhD from the Faculty of Medicine of the University of Hong Kong under the supervision of Professor Ruhong Leung. Postdoctoral research at Massachusetts General Hospital, Harvard University, 2015-2019, with David Scadden as co-supervisor; 2019-2024 Research Assistant Professor at the University of Hong Kong. He joined Zhongshan Medical College in 2024.
The main purpose of this study is to study the molecular regulatory mechanism of the occurrence and recurrence of Acute Myeloid Leukemia (including epigenetic, metabolic and immune interactions) and develop corresponding treatment programs to improve the treatment outcome of leukemia. The relevant research results were published as the first author or corresponding author in high-level journals such as Blood and Leukemia.

Academic achievement

Representative author (*co-first author; #corresponding author)

1. Zeng X, Wang YP, Man CH#. Metabolism in Hematopoiesis and Its malignancy. Adv Exp Med Biol. 2023:1442:45-64
2. Man CH*#, Lam W*, Dang CC*, Zeng X, Zheng L, Chan NM, Ng KL, Chan KC, Kwok TH, Ng TC, Leung WY, Huen SY, Wong CL, So CC, Dou Z, Goyama S, Bray MR, Mak TW, Leung AY. Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML. Blood. 2023 Dec 7;142(23):2002-2015
3. Man CH*#, Zeng X*, Lam W*, Ng TC, Kwok TH, Dang KC, Leung TW, Ng NK, Lam SS, Cher CC, Leung AY. Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication. Leukemia. 2022 Aug;36(8):1990-2001. doi: 10.1038/s41375-022-01606-0
4. Man CH*, Mercier FE, Liu N, Dong W, Stephanopoulos G, Jiang L, Jung Y, Lin CP, Leung AY, Scadden DT. Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive hematopoietic progenitor growth. Blood. 2022 Jan 27;139(4):502-522. doi: 10.1182/blood.2021011563
5. Man CH*, Wan HX*, Fung TK*, Chow HC, Fan AC, Wan TS, Tanaka T, So CW, Kwong YL, Leung AY. Suppression of SOX7 by DNA methylation and its tumor suppressive role in acute myeloid leukemia. Blood. 2015;125:3928-36. doi:10.1182/blood-2014-06-580993
6. Gill H*, Man CH*, Ip AH, Choi WW, Chow HC, Kwong YL, Leung AY. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-Like Tyrosine Kinase-3 internal tandem duplication positive acute myeloid leukemia. Haematologica. 2015;100:e250-3. doi: 10.3324/haematol.2014.123034.
7. Man CH*, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, Leung AY. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD AML. Blood. 2014;123:2530-9. doi: 10.1182/blood-2013-07-512194
8. Man CH*, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness. Blood. 2012;119:5133-43. doi: 10.1182/blood-2011-06-363960